MedTrace Logo

A Study to Evaluate the Neovista Ophthalmic System for the Treatment of Subfoveal CNV in Patients With AMD That Have Failed Primary Anti-VEGF Therapy

NCT00679445 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-07-27

No results posted yet for this study

Summary

The objective of this clinical study is to evaluate the safety and feasibility of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) in patients with age related macular degeneration that have failed Primary Anti-VEGF therapy.

Conditions

Interventions

DEVICE

NeoVista Ophthalmic System

A single procedure using the NeoVioasta Ophthalmic System plus an injection of Lucentis.

Sponsors & Collaborators

  • NeoVista

    lead INDUSTRY

Principal Investigators

  • Jeffrey S Heier, MD · Ophthalmic Consultants of Boston

  • Jeffrey A Nau, MMS · NeoVista, Inc

  • Michael Singer, MD · Medical Center Ophthalmology Associates

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00679445 on ClinicalTrials.gov